A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients

Morticia N. Becx; Noémie S. Minczeles; Tessa Brabander; Wouter W. de Herder; Julie Nonnekens; Johannes Hofland

doi:10.3390/cancers14235792

A Clinical Guide to Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE in Neuroendocrine Tumor Patients

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

49 Citations (Scopus)

416 Downloads (Pure)

Abstract

Peptide receptor radionuclide therapy (PRRT) with [¹⁷⁷Lu]Lu-[DOTA⁰,Tyr³]-octreotate (¹⁷⁷Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (SSTR)-positive advanced well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Clinical evidence of the efficacy of PRRT in tumor control has been proven and lower risks of disease progression or death are seen combined with an improved quality of life. When appropriate patient selection is performed, PRRT is accompanied by limited risks for renal and hematological toxicities. Treatment of NET patients with PRRT requires dedicated clinical expertise due to the biological characteristics of PRRT and specific characteristics of NET patients. This review provides an overview for clinicians dealing with NET on the history, molecular characteristics, efficacy, toxicity and relevant clinical specifics of PRRT.

Original language	English
Article number	5792
Journal	Cancers
Volume	14
Issue number	23
DOIs	https://doi.org/10.3390/cancers14235792
Publication status	Published - 24 Nov 2022

Bibliographical note

Funding Information:
This work was supported by Oncode Institute (grant number P2019-0035).

Publisher Copyright: © 2022 by the authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3390/cancers14235792Licence: CC BY

cancers-14-05792-v2Final published version, 854 KBLicence: CC BY

Cite this

@article{27fe10eb7e794612805c6ba59f44acc8,

title = "A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients",

abstract = "Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (SSTR)-positive advanced well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Clinical evidence of the efficacy of PRRT in tumor control has been proven and lower risks of disease progression or death are seen combined with an improved quality of life. When appropriate patient selection is performed, PRRT is accompanied by limited risks for renal and hematological toxicities. Treatment of NET patients with PRRT requires dedicated clinical expertise due to the biological characteristics of PRRT and specific characteristics of NET patients. This review provides an overview for clinicians dealing with NET on the history, molecular characteristics, efficacy, toxicity and relevant clinical specifics of PRRT.",

author = "Becx, \{Morticia N.\} and Minczeles, \{No{\'e}mie S.\} and Tessa Brabander and \{de Herder\}, \{Wouter W.\} and Julie Nonnekens and Johannes Hofland",

note = "Funding Information: This work was supported by Oncode Institute (grant number P2019-0035). Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = nov,

day = "24",

doi = "10.3390/cancers14235792",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "23",

}

TY - JOUR

T1 - A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients

AU - Becx, Morticia N.

AU - Minczeles, Noémie S.

AU - Brabander, Tessa

AU - de Herder, Wouter W.

AU - Nonnekens, Julie

AU - Hofland, Johannes

PY - 2022/11/24

Y1 - 2022/11/24

N2 - Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (SSTR)-positive advanced well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Clinical evidence of the efficacy of PRRT in tumor control has been proven and lower risks of disease progression or death are seen combined with an improved quality of life. When appropriate patient selection is performed, PRRT is accompanied by limited risks for renal and hematological toxicities. Treatment of NET patients with PRRT requires dedicated clinical expertise due to the biological characteristics of PRRT and specific characteristics of NET patients. This review provides an overview for clinicians dealing with NET on the history, molecular characteristics, efficacy, toxicity and relevant clinical specifics of PRRT.

AB - Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (SSTR)-positive advanced well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Clinical evidence of the efficacy of PRRT in tumor control has been proven and lower risks of disease progression or death are seen combined with an improved quality of life. When appropriate patient selection is performed, PRRT is accompanied by limited risks for renal and hematological toxicities. Treatment of NET patients with PRRT requires dedicated clinical expertise due to the biological characteristics of PRRT and specific characteristics of NET patients. This review provides an overview for clinicians dealing with NET on the history, molecular characteristics, efficacy, toxicity and relevant clinical specifics of PRRT.

UR - https://www.scopus.com/pages/publications/85143612349

U2 - 10.3390/cancers14235792

DO - 10.3390/cancers14235792

M3 - Review article

C2 - 36497273

AN - SCOPUS:85143612349

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 23

M1 - 5792

ER -